GC녹십자

G r e a t C h a l l e n g e .

The world’s first vaccine for hemorrhagic fever with renal syndrome The world’s second vaccine for varicella The world’s third vaccine for hepatitis-B The world’s fourth quadrivalent vaccine for flu Great Challenge toward the world, GC Biopharma Learn More >>

For paths that have not yet been taken,
there lie two opposing attitudes:
Fear that the path ahead is unknown,
and savor the excitement of pioneering
a new path from the unknown

At GC Biopharma, our core mission revolves around one fundamental question: How can we accelerate the development of new drugs that patients have been eagerly anticipating? As trailblazers in the field of bio-pharmaceuticals, we take great pride in our ability to continuously develop groundbreaking plasma derivatives, vaccines, and recombinants. Through unwavering dedication to innovation, GC Biopharma has earned its place among the world's leading providers of life science solutions.

A global research center leading biotechnology R&D

The R&D Division is dedicated to the discovery of early drug candidates as well as conducting early process research and non-clinical development to confirm efficacy and toxicity. The MSAT Division focuses primarily on conducting late-process research. By splitting the R&D laboratory into these two specialized divisions, GC Biopharma aims to foster a powerful synergy within its R&D efforts to propel itself as a prominent global pharmaceutical company. The R&D Division has established a global bridgehead for new drug development by adding business development work to facilitate licensing and joint ventures.

Empowering Access: Localizing Cutting-Edge Treatments for Hepatitis-B, Hemophilia, and Other Diseases

Since its inception in 1982, GC Biopharma has become a pioneering force in the biologics market, leading the way in recombinant proteins and achieving remarkable milestones. As a result, it has succeeded in developing a novel influenza vaccine, seasonal flu vaccine, and a third-generation gene recombination therapy for hemophilia, as well as the world's second-ever treatment for Hunter syndrome using its technologies. In addition to these amazing developments, vital pharmaceuticals such as IV-Globulin (IVIG), Albumin, Hepabig, Antithrombin-III, Greeplast, and many others have grown to be essential revenue generators, bolstering its financial stability and furthering its mission to improve global healthcare outcomes.

GC Biopharma established the largest R&D facility in the Korean pharmaceutical industry.

The new GC Biopharma R&D Center was established in 2013, becoming Korea's largest pharmaceutical R&D facility. The multi-floor complex sprawls over an impressive total floor area of 28,510 𝑚² . It features facilities dedicated to new drug developments, testing manufacturing processes, producing non-clinical testing agents, and specialized analyses. These facilities include state-of-the-art research facilities and office areas, maximizing efficiency within its R&D.

G r e a t C o m m i t m e n t .

A treatment for rare Hunter syndrome (only 2,000 patients nationwide) A specialized flu vaccine for seniors aged 65+ A treatment for hemophilia, a rare disease that afflicts one in 10,000 Great Commitment for humanity, GC Biopharma Learn More >>

Making drugs that are difficult to make,
Pioneering new groundbreaking
pathways forward

GC Biopharma has helped spearhead the development of drugs that are extremely difficult to make. We embrace the challenge as it frees patients from the despair of diseases. With our pioneering spirit, GC Biopharma continues to advance technology and develop specialized drugs that other pharmaceutical companies tend to avoid. We believe in the value of a society where everyone's quality of life is enhanced. We endeavor forward to achieve these goals globally.

A treatment for Hunter syndrome,
a rare disease that affects only 2,000 patients nationwide

Hunterase, the second-ever treatment worldwide for Hunter syndrome, was developed and approved by the Korean Ministry of Food and Drug Safety in 2012. This development epitomizes GC Biopharma's advancement in bio-pharmaceutical technology. We plan to launch this innovative drug into the global market.

Treatment for Hemophilia A, a rare disease that affects 1/10,000 patients nationwide

Greengene F is a third-generation recombinant protein treatment for Hemophilia A, and the third treatment in the world has been developed. Epitomizing GC Biopharma's unrivaled technology and expertise, Phase 3 of clinical trials has reached completion in China. Greengene F was submitted to the Chinese regulatory agency and is under review. Upon launch, Greengene F will generate immense value and growth potential in the Chinese pharmaceutical market.

A specialized flu vaccine for seniors 65 and older

GC Biopharma has set out to research and develop a flu vaccine with a higher dosage for seniors. While standard flu vaccines typically elicit immune responses in 70 to 90 percent of healthy adults under 65, people aged 65 or older tend to exhibit a significantly lower immune response to these vaccines. The development of a more effective flu vaccine for this age group holds the potential to reduce the societal cost of influenza epidemics significantly.

G r e a t C o m p a n y .

A producer of a varicella vaccine that is popular worldwide A seasonal flu vaccine that is revolutionizing the Korean and international markets An innovative recombinant protein drug for hemophilia And the world’s first verified immune cell treatment for liver cancer Great Company globally known, GC Biopharma Learn More >>

Over the last 50 years
To the next 50 years
For the 100 years of humanity
Lies the path of a centennial enterprise

GC embodies its commitment and preparation for the next 50 years through a comprehensive mid- and long-term 2030 plan. This strategy represents five new global medicines, aiming to achieve 5 trillion won in sales and generate a corporate value of 50 trillion won. The goal is to establish ourselves as a leading company in the global health industry. Having already etched a new chapter in the history of the Korean pharmaceutical sector, GC now sets its sights on a transformative vision for the next half-century, driven by its profound mission and dedication to human health.

The great spirit for GC Biopharma's enterprise

For as long as we have walked in the last half century, we will continue treating diseases and improving people's health by developing medicines for patients that might be difficult but essential. GC's vision is to maximize the effectiveness and value of existing products. At the same time, we pave our path forward, strengthening the pipeline of new specialty medicines dedicated to various diseases which provide a healthier life for people globally.

이메일집단수집거부

GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일

Pharmaceutical

GC MS

GC Wellbeing

GC Medis
Healthcare

GC Cell

GC Genome
Overseas

GC China Pharm

Curevo

GC Pharma do Brasil
Foundation

MOGAM Institue

GC Labs

GC i-Med
Others

GC Invacfarm

For paths that have not yet been taken,there lie two opposing attitudes:Fear that the path ahead is unknown,and savor the excitement of pioneeringa new path from the unknown